rombotic Therapy
for Vascular Diseases. Eur J Vasc Endovasc Surg 2023;65:627-89.
138. Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F,
et al. Rationale, design and baseline characteristics of participants
in the cardiovascular outcomes for people using anticoagulation
strategies (COMPASS) trial. Can J Cardiol 2017;33:1027-35.
139. Ambler GK, Nordanstig J, Behrendt C-A, Twine CP. Network metaanalysis of the beneﬁt of aspirin with rivaroxaban vs. clopidogrel
for patients with stable symptomatic lower extremity arterial disease. Eur J Vasc Endovasc Surg 2021;62:654-5.
140. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR,
Patel MR, et al. Rivaroxaban in peripheral artery disease after
revascularization. N Engl J Med 2020;382:1994-2004.
141. Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS,
et al. Rivaroxaban and aspirin in peripheral artery disease lower
extremity revascularization: impact of concomitant clopidogrel on
efﬁcacy and safety. Circulation 2020;142:2219-30.
142. Group DBOAoAS. Efﬁcacy of oral anticoagulants compared with
aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral
Anticoagulants or Aspirin Study): a randomised trial. Lancet
2000;355:346-51.
143. Arnott C, Huang Y, Neuen BL, Di Tanna GL, Cannon CP, Oh R, et al.
The effect of canagliﬂozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obes Metab 2020;22:
17